Regeneron Pharmaceuticals (NQ:REGN)

813.27 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

66 67 Next >

REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

July 23, 2026

From Levi & Korsinsky, LLP

Via Business Wire

Did You Lose Money Investing in Regeneron Pharmaceuticals, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against REGN

July 23, 2026

San Diego, California--(Newsfile Corp. - July 23, 2026) - Robbins LLP reminds stockholders that a class action was filed on...

Via Newsfile

Topics Earnings

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces a Securities Fraud Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)

July 23, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

REGN (NASDAQ:REGN) Presents a Classic Value Opportunity with Strong Fundamentals ↗

June 12, 2026

Via Chartmill

REGN INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026

July 23, 2026

From Faruqi & Faruqi, LLP

Via Business Wire

REGENERNON PHARMACEUTICALS, INC. INVESTORS WITH LOSSES HAVE UNTIL SEPTEMBER 14, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

July 22, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

REGN Breaking News: Regeneron Inc. Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA Law

July 21, 2026

From Bleichmar Fonti & Auld LLP

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN

July 21, 2026

From Pomerantz LLP

Via GlobeNewswire

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

July 21, 2026

From Schall Law

Via GlobeNewswire

REGENERNON PHARMACEUTICALS, INC. (REGN) INVESTOR ALERT Investors With Large Losses in Regeneron Pharmaceuticals, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

July 20, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REGN

July 18, 2026

From DJS Law Group

Via Business Wire

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

July 17, 2026

From The Schall Law Firm

Via Business Wire

REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

July 17, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

REGN DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026

July 17, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

3 High-Yield Dividend Stocks to Buy and Hold ↗

July 17, 2026

All three can be bought on the dip.

Via The Motley Fool

Topics Intellectual Property

Investor Notice: Robbins LLP Informs Investors of the Regeneron Pharmaceuticals, Inc. Class Action Lawsuit

July 16, 2026

From Robbins LLP

Via Business Wire

1 Large-Cap Stock with Exciting Potential and 2 We Turn Down

July 14, 2026

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it m...

Via StockStory

Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right. ↗

July 02, 2026

Analysts have given Alnylam Pharmaceuticals an average price target of $436.

Via The Motley Fool

Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57% ↗

July 01, 2026

It might pull it off, provided several things fall right in place.

Via The Motley Fool

Hormuz Goes Quiet, Software Wakes Up, and Burry Picks a Side ↗

June 29, 2026

Via Chartmill

Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could ↗

June 29, 2026

These stocks are better bets to skyrocket than the much-hyped rocket stock.

Via The Motley Fool

This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested ↗

June 27, 2026

Parabilis Medicines is ambitious, but it has Regeneron on its side already.

Via The Motley Fool

Topics Initial Public Offering

Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

June 25, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

2 Underrated Weight Loss Stocks to Buy and Hold ↗

June 23, 2026

They look well-positioned to grab a slice of the fast-growing anti-obesity market.

Via The Motley Fool

Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

June 22, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

This Stock Is Up 58% This Year. Is It too Late to Buy? ↗

June 17, 2026

There could be additional catalysts for this drugmaker over the next year.

Via The Motley Fool

3 Profitable Stocks We Think Twice About

June 17, 2026

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

Via StockStory

REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

June 10, 2026

From The Schall Law Firm

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

June 09, 2026

From Pomerantz LLP

Via GlobeNewswire

Top S&P500 movers in Monday's session ↗

June 08, 2026

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

66 67 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.